-
Vidéo | 2025.06.10
Avian flu: should we be worried?
Avian flu is all over the news... but what is the real risk to humans?Marie-Anne Welti, head of the Molecular Mechanisms of Pneumovirus Multiplication unit at the Institut Pasteur, takes stock of the current situation.The H5N1 virus, responsible for avian flu, mainly affects birds, but has also been detected in farmed mammals, such as dairy cows in the USA since 2024.In France, cases were...
-
Document de presse | 2015.01.26
Patronage: the Institut Pasteur and the Total Foundation renew their common commitment against infectious diseases
For 10 years, Total and its corporate foundation working alongside the Institut Pasteur and its International Network in the fight against infectious diseases. A new sponsorship agreement, of EUR 6 million for three years, was signed on 26 January 2015. It will provide funding, for public health and research projects in resource limited countries in order to better understand the therapeutic and...
-
Article | 2017.03.21
We need you
Making a donation to the Institut Pasteur means contributing to new breakthroughs in biomedical research and playing your own part in the work and discoveries of scientists.
-
News | 2017.11.14
130 years ago, the Institut Pasteur was under construction
On June 4, 1887, the Institut Pasteur was created following the success of the rabies vaccine developed by Louis Pasteur – and thanks to the generous support of countless donors. Just set up as an institution with official charitable status, the building work began straight away."This is the start of post-exposure rabies prophylaxis. (...) A rabies vaccine center should be set up," declared Louis...
-
Article | 2020.08.20
Industrial property
The Institut Pasteur is in the world's top 10 list for US and European patents granted in the field of life sciences for the period 2010-2014.
-
Document de presse | 2021.03.26
COVID-19: analysis of the sensitivity of the UK (B.1.1.7) and South African (B.1.351) variants to SARS-CoV-2 neutralizing antibodies
The B.1.1.7 and B.1.351 variants of SARS-CoV-2 were first detected in the UK and South Africa respectively, and have since spread to many other countries. Scientists from the Institut Pasteur joined forces with Orléans Regional Hospital, Tours University Hospital, Créteil Intercommunal Hospital, Strasbourg University Hospital and Georges Pompidou European Hospital to study the sensitivity of...
-
News | 2020.02.05
Meningococci: an example of genomics used as an epidemiological tool
By examining vaccine coverage of invasive meningococcal infections in conjunction with genomic and pathophysiological analyses, it was possible to detect a new genotype in meningococcal serogroup W and characterize the emergence of the resulting bacterial strain. This combined approach has been a useful decision-making tool in implementing measures to control invasive meningococcal infections in...
-
News | 2022.04.14
Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern
SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...
-
Article | 2025.01.20
Immunology
The complexity of the immune system is a never-ending source of fascination for scientists. The Department of Immunology is composed of teams that investigate the body's natural system of protection against disease.
-
Document de presse | 2016.03.03
Antibodies capable of eliminating HIV-infected cells
Researchers from the Institut Pasteur, CNRS and Vaccine Research Institute (ANRS/Inserm) have recently shown that some effective antibodies recognize cells infected by the human immunodeficiency virus (HIV) and trigger their destruction by the immune system. This discovery sheds new light on the mechanism of action of these specific antibodies, which are currently undergoing clinical trials....